Loading
A phase 3 trial of Neladalkib, Alectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvalent Inc., now recruiting.
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC is a phase 3 interventional study registered as NCT06765109 by Nuvalent Inc., with 450 participants planned, started 2025-07-17 and due to reach its primary completion in 2029-12. Interventions recorded: Neladalkib (NVL-655), Alectinib. Conditions listed: Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive. No results are recorded here; the registry entry is the source.
Shares Neladalkib, Nuvalent, ALK-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares NVL, Nuvalent, Small-molecule kinase inhibitors.
Shares Alectinib, ALK-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Alectinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Nuvalent, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Alectinib, Small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Alectinib, ALK-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.